Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1 - PubMed (original) (raw)
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1
F Wang et al. J Virol. 1990 Jul.
Abstract
Several lines of evidence are compatible with the hypothesis that Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) or leader protein (EBNA-LP) affects expression of the EBV latent infection membrane protein LMP1. We now demonstrate the following. (i) Acute transfection and expression of EBNA-2 under control of simian virus 40 or Moloney murine leukemia virus promoters resulted in increased LMP1 expression in P3HR-1-infected Burkitt's lymphoma cells and the P3HR-1 or Daudi cell line. (ii) Transfection and expression of EBNA-LP alone had no effect on LMP1 expression and did not act synergistically with EBNA-2 to affect LMP1 expression. (iii) LMP1 expression in Daudi and P3HR-1-infected cells was controlled at the mRNA level, and EBNA-2 expression in Daudi cells increased LMP1 mRNA. (iv) No other EBV genes were required for EBNA-2 transactivation of LMP1 since cotransfection of recombinant EBNA-2 expression vectors and genomic LMP1 DNA fragments enhanced LMP1 expression in the EBV-negative B-lymphoma cell lines BJAB, Louckes, and BL30. (v) An EBNA-2-responsive element was found within the -512 to +40 LMP1 DNA since this DNA linked to a chloramphenicol acetyltransferase reporter gene was transactivated by cotransfection with an EBNA-2 expression vector. (vi) The EBV type 2 EBNA-2 transactivated LMP1 as well as the EBV type 1 EBNA-2. (vii) Two deletions within the EBNA-2 gene which rendered EBV transformation incompetent did not transactivate LMP1, whereas a transformation-competent EBNA-2 deletion mutant did transactivate LMP1. LMP1 is a potent effector of B-lymphocyte activation and can act synergistically with EBNA-2 to induce cellular CD23 gene expression. Thus, EBNA-2 transactivation of LMP1 amplifies the biological impact of EBNA-2 and underscores its central role in EBV-induced growth transformation.
Similar articles
- Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E. Wang F, et al. J Virol. 1990 May;64(5):2309-18. doi: 10.1128/JVI.64.5.2309-2318.1990. J Virol. 1990. PMID: 2157887 Free PMC article. - Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.
Cohen JI, Wang F, Kieff E. Cohen JI, et al. J Virol. 1991 May;65(5):2545-54. doi: 10.1128/JVI.65.5.2545-2554.1991. J Virol. 1991. PMID: 1850028 Free PMC article. - Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes.
Rooney CM, Brimmell M, Buschle M, Allan G, Farrell PJ, Kolman JL. Rooney CM, et al. J Virol. 1992 Jan;66(1):496-504. doi: 10.1128/JVI.66.1.496-504.1992. J Virol. 1992. PMID: 1309259 Free PMC article. - Immortalizing genes of Epstein-Barr virus.
Middleton T, Gahn TA, Martin JM, Sugden B. Middleton T, et al. Adv Virus Res. 1991;40:19-55. doi: 10.1016/s0065-3527(08)60276-6. Adv Virus Res. 1991. PMID: 1659776 Review. - EBNA2 and Its Coactivator EBNA-LP.
Kempkes B, Ling PD. Kempkes B, et al. Curr Top Microbiol Immunol. 2015;391:35-59. doi: 10.1007/978-3-319-22834-1_2. Curr Top Microbiol Immunol. 2015. PMID: 26428371 Review.
Cited by
- Biogenesis of Epstein-Barr virus microRNAs.
Kim DN, Lee SK. Kim DN, et al. Mol Cell Biochem. 2012 Jun;365(1-2):203-10. doi: 10.1007/s11010-012-1261-7. Epub 2012 Feb 18. Mol Cell Biochem. 2012. PMID: 22350759 - EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.
Riley KJ, Rabinowitz GS, Yario TA, Luna JM, Darnell RB, Steitz JA. Riley KJ, et al. EMBO J. 2012 May 2;31(9):2207-21. doi: 10.1038/emboj.2012.63. Epub 2012 Mar 30. EMBO J. 2012. PMID: 22473208 Free PMC article. - The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.
Banerjee S, Lu J, Cai Q, Saha A, Jha HC, Dzeng RK, Robertson ES. Banerjee S, et al. PLoS Pathog. 2013;9(5):e1003314. doi: 10.1371/journal.ppat.1003314. Epub 2013 May 2. PLoS Pathog. 2013. PMID: 23658517 Free PMC article. - Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
Hutchings IA, Tierney RJ, Kelly GL, Stylianou J, Rickinson AB, Bell AI. Hutchings IA, et al. J Virol. 2006 Nov;80(21):10700-11. doi: 10.1128/JVI.01204-06. Epub 2006 Aug 18. J Virol. 2006. PMID: 16920819 Free PMC article. - Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.
Chen W, Cooper NR. Chen W, et al. J Virol. 1996 Jul;70(7):4849-53. doi: 10.1128/JVI.70.7.4849-4853.1996. J Virol. 1996. PMID: 8676521 Free PMC article.
References
- N Engl J Med. 1977 Nov 17;297(20):1077-80 - PubMed
- J Virol. 1988 Nov;62(11):4173-84 - PubMed
- N Engl J Med. 1989 Oct 19;321(16):1080-5 - PubMed
- Proc Natl Acad Sci U S A. 1989 Dec;86(23):9558-62 - PubMed
- J Virol. 1990 Mar;64(3):1002-13 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources